Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation

Biology of Blood and Marrow Transplantation

Volumn 4, Issue 1, 1998, Pages 20-26

  Sullivan, Keith M ^a,b   Kansu, Emin ^a   Storer, Barry ^a,b   Jocom, Jane ^a   Emerson, Geoff ^a   Reagan, Tara ^a   Emerson, Vaughn ^a   Siadak, Muriel F ^a   Davis, Chris ^a,b   Appelbaum, Frederick R ^a,b   Buckner, C Dean ^a   Hansen, John A ^a,b   Shulman, Howard M ^a,b   Storb, Rainer ^a,b   McDonald, George B ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Liver toxicity of high dose cytoreductive therapy; Myeloablative conditioning regimen

Indexed keywords

IMMUNOGLOBULIN;

ALLOTRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; HUMAN; LIVER VEIN OBSTRUCTION; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

BONE MARROW TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0031604990     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(98)90006-4     Document Type: Article

References (43)

1. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED: Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4:116, 1984.
2. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R: Veno-oclussive disease of the liver following bone marrow transplantation. Transplantation 44:778, 1987.
3. Bearman SI, Appelbaum FR, Back A, Petersen FB, Buchner CD, Sullivan KM, Schoch GH, Fisher LD, Thomas ED: Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 7:1288, 1989.
4. Shulman HM, Hinterberger W: Hepatic veno-occlusive disease liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 10:197, 1992. [review]
5. Bearman SI, Appelbaum FR, Buchner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562, 1988.
6. Nevill TJ, Barnett MJ, Klingemann GH, Reece DE, Shepherd JD, Phillips GL: Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 9:1224, 1991.
7. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB: Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 11:1729, 1993.
8. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multi-organ failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118:255, 1993.
9. Bearman SI: The syndrome of hepatic veno-occlusive disease after bone marrow transplantation. Blood 85:3005, 1995.
10. Clift RA, Buchner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Sanden J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas ED: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76:1867, 1990.
11. Clift RA, Buchner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Meyers J, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas ED: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 77:1660, 1991.
12. Essell JH, Thompson JN, Harman GS, Johnson RA, Rubinsak JR: Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 79:2784, 1992.
13. Kami M, Mori S, Tanikawa S, Akiyama H, Onozawa Y, Tanaka T, Okamoto R, Maeda Y, Sasaki T, Kaku H, Matsuura Y, Hiruma K, Sakamaki H: Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution. Bone Marrow Transplant 20:397, 1997.
14. Klaesson S, Ringden O, Ljungman P, Aschan J, Hagglund H, Winiarski J: Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation 60:1225, 1995.
15. Rozman C, Carreras E, Qian C, Gale RP, Bonin MM, Rowlings PA, Ash RC, Champlin RE, Henslee-Downey PJ, Herzig RH, Hinterberger W, Klein JP, Prentice HG, Reiffers J, Zwaan FE, Horowitz MM: Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 17:75, 1996.
16. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buchner CD, Meyers JD, Counts GW, Bowden RA, Petersen FB, Witherspoon RP, Budinger MD, Schwartz RS, Appelbaum FR, Clift RA, Hansen JA, Sanders JE, Thomas ED, Storb R: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705, 1990.
17. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, Siadak M, Nims J, Witherspoon RP, Anasetti C, Appelbaum FR, Bowden RA, Buckner CD, Crawford SW, Deeg HJ, Hansen JA, McDonald GB, Sanders JE, Storb R: A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 2:44, 1996.
18. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone marrow transplantation. N Engl J Med 292:832, 1975.
19. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone marrow transplantation. N Engl J Med 292:895, 1975.
20. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan KM, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986.
21. Goodrich JM, Boeckh M, Bowden R: Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 19:287, 1994.
22. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA: Efficacy and safety of fluconazole for fungal infections after marrow transplant - a prospective, randomized, double-blind study. J Infect Dis 171:1545, 1995.
23. Armitage JO: Bone marrow transplantation. N Engl J Med 330:827, 1994.
24. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb K, Sullivan KM, Anasetti C: Unrelated donor marrow transplants for patients with chronic myeloid leukemia in chronic phase. N Engl J Med 338:962, 1998.
25. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, Thomas ED: An analysis of hepatic veno-occlusive disease and centrolobular hepatic degeneration following bone marrow transplantation. Gastroenterology 79:1178, 1980.
26. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen T-L, Saral R, Santos GW, Colvin OM: Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25:55, 1989.
27. DeLeve LD, Kaplowitz N: Mechanisms of drug-induced liver disease. Gastroenterology Clin North Am 24:787, 1995.
28. DeLeve LD: Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 24:830, 1996.
29. Slatter JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI, Anasetti C, Appelbaum FR: Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 14:1484, 1996.
30. Dulley FL, Kaftner EJ, Appelbaum FR, Amos D, Hill RS, Buckner CD, Shulman HM, McDonald GB, Thomas ED: Veno-occlusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 43:870, 1987.
31. Yee GC, McGuire TR, Gmur DJ, Lennon TP, Deeg HJ: Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation: influence of age, obesity and hematocrit. Transplantation 46:399, 1988.
32. Deeg HJ, Seidel K, Bruemmer B, Pepe MS, Appelbaum FR: Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 15:461, 1995.
33. Fleming DR, Rayens MK, Garrison J: Impact of obesity on allogeneic stem cell transplant patients: a matched case-controlled study. Am J Med 102:265, 1997.
34. Petersen FB, Deeg HJ, Buckner CD, Appelbaum FR, Storb R, Clift RA, Sanders JE, Bensinger WI, Witherspoon RP, Sullivan KM, Doney K, Hansen JA: Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide - a phase I trial. Int J Radiat Oncol Biol Phys 23:1027, 1992.
35. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, Lebmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brebm G, Mittermuller J, Wilmanns W: Increased serum levels of rumor necrosis factor alpha precedes major complications of bone marrow transplantation. Blood 75:1011, 1990.
36. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964, 1992.
37. van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322:1622, 1990.
38. Dwyer JM: Manipulating the immune system with immune globulin. N Engl J Med 326:107, 1991.
39. Abe YK, Horiuchi A, Miyake M, Kimura S: Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139:5, 1994.
40. Aukrust P, Froland SS, Liabakk N-B, Muller F, Nordoy I, Hang C, Espevik T: Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84:2136, 1994.
41. Winston DJ, Ho WG, Lin C-H, Bartoni K, Budinger MD, Gale RP, Champlin RE, : Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106:12, 1987.
42. Graham-Pole J, Camitta B, Casper J, Elfenbein G, Gross S, Herzig R, Koch P, Mahoney D, Marcus R, Munoz L, Pick T, Spruce W, Steuber P, Weiner R: Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. Bone Marrow Transplant 3:559, 1988.
43. Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, Wingard JR: Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 12:273, 1993.